Legacy Advisors’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
Other funds holding AZN
Legacy Advisors's AZN Position: Q3 2026 in Review
Legacy Advisors sold out of AstraZeneca (AZN) in Q3 2026, closing a stake of 1,283 shares — an estimated $243K sold.
Legacy Advisors first reported a position in AZN in Q3 2017 and held it in 3 quarters. The position peaked at $243K in Q2 2026. 1,446 funds tracked by Wall St. Rank hold AZN as of Q3 2026.
- Legacy Advisors reported no remaining AstraZeneca position as of Q3 2026 after selling out during the quarter.
- Legacy Advisors sold 1,283 AstraZeneca shares in Q3 2026, an estimated $243K.
- Legacy Advisors first reported a position in AstraZeneca in Q3 2017 and held it in 3 quarters.
- Legacy Advisors's AstraZeneca position peaked at $243K in Q2 2026.
- 1,446 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2026.
Based on Legacy Advisors's 13F filing for Q3 2026, filed 19 Oct 2026.